Key takeaways for Connecticut
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • HUSKY Health coverage rules apply for Cardiovascular Risk Reduction patients in Connecticut — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
Connecticut-specific context
Connecticut has telehealth access concentrated in Bridgeport, New Haven, Stamford metros, with additional reach to Hartford and Waterbury. Yale New Haven Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at portal.ct.gov/dph.
Connecticuttelehealth & pricing rules
- • Connecticut requires a live video consultation before a GLP-1 prescription.
- • Connecticut allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Connecticut: ~$325/mo (compounded options often lower, brand higher).